Sarcoidosis. Disease progression based on radiological and functional course: Predictive factors.

Autor: Casal A; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: ana.casal.mourino@sergas.es., Suárez-Antelo J; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain., Soto-Feijóo R; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: roi.soto.feijoo@sergas.es., Ferreiro L; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain; Health Research Institute (IDIS), Santiago de Compostela, Spain. Electronic address: lferfer7@gamial.com., Rodríguez-Núñez N; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: nuria.rodriguez.nunez@sergas.es., Lama A; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: adriana.lama.lopez@sergas.es., Riveiro V; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: vanessa.riveiro.blanco@sergas.es., Toubes ME; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: maria.elena.toubes.navarro@sergas.es., Lourido T; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: tamara.lourido.cebrerio@sergas.es., Ricoy J; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: jorge.ricoy.gabaldon@sergas.es., Rábade C; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: carlos.rabade.castedo@sergas.es., Zamarrón C; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: carlos.zamarron.sanz@sergas.es., Rodríguez C; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: carlota.rodriguez.garcia@sergas.es., Abelleira R; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: romina.abelleira.paris@sergas.es., Álvarez-Dobaño JM; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain; Health Research Institute (IDIS), Santiago de Compostela, Spain. Electronic address: jad01po@hotmail.com., Golpe A; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain; Health Research Institute (IDIS), Santiago de Compostela, Spain. Electronic address: antonio.golpe.gomez@sergas.es., de Alegría AM; Radiology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: anxo.martinez.de.alegria.alonso@sergas.es., Antúnez JR; Anatomical Pathology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: jose.ramon.antunez.lopez@sergas.es., Gude F; Health Research Institute (IDIS), Santiago de Compostela, Spain; Clinical Epidemiology Unit, Hospital Clínico Universitario, Santiago de Compostela, Spain. Electronic address: francisco.gude.sampedro@sergas.es., Valdés L; Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain; Health Research Institute (IDIS), Santiago de Compostela, Spain; University of Santiago de Compostela. Electronic address: luis.valdes.cuadrado@sergas.es.
Jazyk: angličtina
Zdroj: Heart & lung : the journal of critical care [Heart Lung] 2022 Nov-Dec; Vol. 56, pp. 62-69. Date of Electronic Publication: 2022 Jun 30.
DOI: 10.1016/j.hrtlng.2022.06.020
Abstrakt: Background: Sarcoidosis is a multiorgan granulomatous disease with a variable course.
Oobjectives: The purpose of this study is to identify the patients that are more likely to experience disease progression.
Methods: A retrospective study in patients ≥18 years. Pulmonary function and radiological stage (Scadding criteria) were assessed at diagnosis, and at 1, 3 and 5 years. Sarcoidosis progression was established based on deterioration of radiological or pulmonary function (decrease ≥10% of FVC and/or ≥15% of diffusing capacity of the lung (DLCO).
Results: The sample included 277 caucasian patients [mean age, 50±13.6; 69.7% between 31-60 years; 56.3% men]. In total, 65% had stage II sarcoidosis, whereas only 8.3% had stage III/IV disease. Mean pulmonary function (FVC, FEV 1 , FEV 1 /FVC and DLCO) at diagnosis was 103±21.8, 96±22.2, 76.2±8 and 81.7±21.7, respectively. The percentage of patients with normal FVC and DLCO was 72.2% and 51.8%, respectively. Radiological stage did not change significantly during follow-up (5 years; p=0.080) and only progressed in 13 patients (5.7%). At 3 years, FVC improved, whereas DLCO exacerbated significantly (p<0.001 for the two). Disease progressed in 34.5% of the patients (57/165) whose pulmonary function and radiological stage were available (both baseline and at 3 years). Age was associated with disease progression [OR=1.04 (95%CI=1.01, 1.06)]. Risk increased by 4% for each year older a patient was at diagnosis.
Conclusions: At 3 years, a third of patients experienced sarcoidosis progression. Age was the only factor associated with disease prognosis.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: